| Buyer |
Acquired |
Target Product |
M&A Price in Millions ($USD) |
| Gilead |
Pharmasset |
Hepatitis C |
$11,000 |
| Bristol-Myers Squibb |
Amylin |
Diabetes market |
$7,000 |
| Watson |
Actavis |
Global generics market |
$5,900 |
| GlaxoSmithKline |
Human Genome Sciences |
Cardiovascular market |
$3,000 |
| Bristol-Myers Squibb |
Inhibitex |
Hepatitis C |
$2,500 |
|